Xeris targets Phase 3 start for once-weekly levothyroxine candidate XP-8121 by year-end

• Xeris outlined its XP-8121 development plan for hypothyroidism, targeting a Phase 3 start by year-end with results due in late 2028.
• Phase 3 results have not been presented; management expects U.S. FDA approval and a commercial launch in 2030.
• The pivotal study aims to show once-weekly subcutaneous dosing can match daily oral levothyroxine control in well-managed patients.
• A pediatric study and a special-population trial are planned to broaden use, including patients who struggle to stabilize on oral therapy.
• Peak net revenue potential was projected at USD 1 billion to USD 3 billion, framing XP-8121 as a major growth driver.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609090830BIZWIRE_USPR_____20260909_BW982377) on September 09, 2026, and is solely responsible for the information contained therein.